Zicam advertised its pre-cold medicines as preventing, shortening and reducing the severity of the symptoms of the common cold.
We filed a class action lawsuit on behalf of purchasers of Zicam pre-cold medicines in the United States alleging that the claims about Zicam were false and misleading and seeking refunds for purchasers. On the eve of trial, we negotiated a $16 million class settlement.
The Court awarded the plaintiff a $10,000 incentive award. Class members received a full cash refund for up to five units of Zicam without proof of purchase. Class members received a full cash refund for six or more units purchased with proof of purchase.